All In Biotech

Drug Trial Radar · NCT02503306

Efficacy and Tolerability Study of Avanafil in Russia

Clinical Trial on Efficacy and Tolerability of Two Different Single Doses of Avanafil in Russia

Last checked: Nov 20, 2026Latest source record: Mar 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

189

Actual

Start

Jul 2015

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: o To assess the change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse between the run-in period and treatment period: * The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina. * The change in score on the erectile function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. Secondary Objective: o To evaluate the safety and tolerability of avanafil in patients with erectile dysfunction (ED).

Conditions

  • Sexual Function and Fertility Disorders NEC-Erectile Dysfunction

Interventions

  • AVANAFILDrug

    Pharmaceutical form:tablets Route of administration: oral

  • placeboDrug

    Pharmaceutical form:tablets Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourseTime frame: 12 weeks
  2. Change in the percentage of sexual attempts in which subjects are able to insert the penis into the partner's vaginaTime frame: 8 weeks
  3. Change from baseline in EF scoreTime frame: baseline and 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.